Repeated large volume paracentesis provides only temporary improvement of symptoms. Symptoms including abdominal pain, dyspnoea, nausea, vomiting, and anorexia have a detrimental impact on the quality of life. The management of the remaining 10% with diuretic resistant ascites is challenging. In 90% of patients, ascites can be treated with diuretics. Ten percent of patients with cirrhosis develop ascites. Condition or diseaseĬirrhosis Ascites Hepatic Ascites (Non-Malignant)ĭevice: PleurX, peritoneal tunnelated catheter Device: Large Volume Paracentesis Drug: Ciprofloxacin 500Mg Tablet The primary outcome is paracentesis free survival. The total duration of follow up is six months.
PERMANENT SERUM SERIAL NUMBER TRIAL
We will include 32 adult patients with cirrhosis Duration of trial 18 months. All patients will receive ciprofloxacin to prevent spontaneous bacterial peritonitis. Tunnelated peritoneal (PleurX) catheter versus large volume paracentesis.
The trial is an investigator initiated, randomised, single blind, parallel arm, controlled trial. This study aims to evaluate the beneficial and harmful effects of the peritoneal catheter (PleurX) versus repeated large volume paracentesis for patients with cirrhosis and diuretic resistant ascites. The treatment may improve the management of ascites and have a beneficial effect on the quality of life. Insertion of a tunnelated peritoneal catheter (PleurX) allows repeated intermittent small volume fluid drainage at home.